A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system.
In this study, children and teenagers with moderate to severe Crohn's disease will be treated
with vedolizumab.
The main aim of the study is to check if participants achieve remission after treatment with
the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no
signs of inflammation.
Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a
clinical response will receive either a high dose or low dose of vedolizumab once every 8
weeks. They will receive the same dose every time.